PDF Version: Riggan
Editor's Note: This article originally appeared in the Volume 16, Number 1, Spring 2009 issue of Dignitas, the Centers quarterly publication. Subscriptions toDignitasare available to CBHD Members. To learn more about the benefits of becoming a member click here.
Umbilical cords have traditionally been viewed as disposable biological by-product.Cord blood, however, is rich in multi-potent hematopoietic stem cells (HSCs).Recent medical advances have indicated that these stem cells found in cord blood can be used to treat the same disorders as the hematopoietic stem cells found in bone marrow and in the bloodstream but without some of the disadvantages of these types of transplants.Cord blood is currently used to treat approximately 70 diseases including leukemias, lymphomas, anemias, andSevere Combined Immunodeficiency (SCID).Six thousand patients worldwide have been treated with cord blood stem cell transplants, although the FDA considers the procedure to be experimental.These multipotent stem cells also show promise for the treatment of a variety of diseases and disorders other than those affecting the blood.
Up to 180 mL of blood can be taken from an umbilical cord for use in stem cell transplants.Due to the experimental nature of cord blood transplants, such transplants are considered on a case-by-case basis.This blood is collected from the umbilical cord, processed,and cryogenically preserved shortly after the umbilical cord is clamped. This blood can be cryogenically preserved for public or private (family) use.Public registries store cord blood donated for availability to the general public for transplantation.Private registries store cord blood on behalf of families who wish to use this blood for the donor infant, siblings, or other family members.Private cord blood banks charge a collection fee (ranging from $1,000-2,000) and an annual storage fee (approximately $150 per year).
The Stem Cell Therapeutic and Research Act was passed in 2005, which supports building a public reserve of 150,000 cord blood units from ethnically diverse donors in order to treat more than 90% of patients in need of HSC transplants.Donors from ethnic minority patients are particularly in need due to the greater variation of HLA-types in non-Caucasian ethnicities. Thirty-five percent of cord blood units go to patients of diverse ethnic and racial backgrounds.
Cord blood does not have to be as closely matched as bone marrow or peripheral blood transplants.Bone marrow transplants typically require a 6/6 HLA match.While a closely matched cord blood transplant is preferable, cord blood has been transplanted successfully with as few as 3/6 matches.For patients with uncommon tissue types, cord blood may be an option if a suitable adult donor cannot be found.Since cord blood is cryogenically preserved and stored, it is more readily available than bone marrow or peripheral blood from an unrelated donor, allowing transplants to take place within a shorter period of time.It takes approximately two weeks to locate, transfer, and thaw a preserved cord blood unit.Finding a suitable bone marrow donor typically takes at least two months.
Graft-versus-host disease (GVHD) is a common complication after an allogeneic transplant (from a source other than the patient) where the patients immune system recognizes the cells as foreign and attacks the newly transplanted cells.This can be a potentially life threatening complication.The risk for developing GVHD is lower with cord blood transplants than with marrow or peripheral blood transplants.Patients who do develop GVHD after a cord blood transplant typically do not develop as severe of a case of GVHD.Cord blood also is less likely to transmit certain viruses such as cytomegalovirus (CMV), which poses serious risks for transplant patients with compromised immune systems.
While the transplantation of cord blood has its advantages, its main disadvantage is the limited amount of blood contained within a single umbilical cord.Because of this, cord blood is most often transplanted in children.Physicians are currently trying to determine ways that cord blood can be used in larger patients, such as transferring two cord blood units or increasing the number of cellsin vitrobefore transplanting to the patient.It also takes longer for cord blood cells to engraft. This lengthier period means that the patient is at a higher risk for infection until the transplanted cells engraft.Patients also cannot get additional donations from the same donor if the cells do not engraft or if the patient relapses.If this is the case, an additional cord blood unit or an adult donor may be used.While cord blood is screened for a variety of common genetic diseases, rare genetic diseases that manifest after birth may be passed on.The National Cord Blood Program estimates that the risk of transmitting a rare genetic disorder is approximately 1 in 10,000.
In addition to the use of cord blood stem cells for transplantation, cord blood stem cells are currently being investigated for use in stem cell therapy.Cord blood stem cells are multipotent and are believed to have greater plasticity (the ability to form into different stem cell types) than adult hematopoietic stem cells found in bone marrow.HSCs are being investigated for use in autoimmune diseases such as diabetes, rheumatoid arthritis, and systemic lupus erythermatosis (SLE) in order to reprogram or reconstitute the immune system.Additionally, research is being conducted on differentiating HSCs into other tissue types such as skeletal and cardiac muscle, liver cells (hepatocytes), and neurons.HSCs are currently being used in gene therapy, due to their self-renewing properties, as a means of delivering genes to repair damaged cells.HSCs are the only cells currently being used in this manner in clinical gene therapy trials.
In addition to the benefits related to transplanting HSCs derived from cord blood, HSCs are relatively easy to isolate, giving them an advantage over other adult stem cell types.Cord blood HSCs are also believed to have greater plasticity than HSCs found in bone marrow or the blood stream.The limits and possibilities of using HSCs to repair tissues and treat non-blood related disorders are currently being studied.
Similar to transplantation, the main disadvantage is the limited number of cells that can be procured from a single umbilical cord.Different ways of growing and multiplying HSCs in culture are currently being investigated.Once this barrier is overcome, HSCs could be used to create universal donor stem cells as well as specific types of red or white blood cells.Immunologic rejection is a possibility, as with any stem cell transplant.HSCs that are genetically modified are susceptible to cancerous formation and may not migrate (home) to the appropriate tissue and actively divide.The longevity of cord blood HSCs is also unknown.
Annotated Bibliography on Umbilical Cord Stem Cell Plasticity: http://www.cordbloodforum.org/biblio/xvi_plasticity/index.html
Introduction to Hematopoietic Stem Cells: http://stemcells.nih.gov/info/scireport/chapter5.asp
Cord blood stem cells are classified as adult (or non-embryonic) stem cells.Embryonic stem cells (ESC) are believed to be more advantageous for thetreatment of disease or injury due to their pluripotent nature; that is, they have the ability to differentiate into all the cells present in the human body derived from the three germ layers (endoderm, mesoderm, and ectoderm).Adult stem cells are multipotent, implyingthat they can only differentiate into a limited number of cells typically within the same family (e.g., hematopoietic stem cells give rise to red blood cells, white blood cells, and platelets).
In the procurement of embryonic stem cells for research, the embryo from which the cells are harvested is destroyed.For those who believe that human life begins at conception this research is obviously unethical.In contrast, adult stem cells can be isolated from tissue from a consenting patient.While cord blood stem cells are classified as adult stem cells, they appear to have greater potency (ability to differentiate into other cell types) than other adult stem cells, making them a potentially valuable option for use in a variety of treatments and therapies.Cord blood stem cells offer some of the advantages of ESCs without any of the ethical drawbacks.Research into the use of cord blood stem cells for the treatment of disease and disability is a promising and ethical avenue of stem cell research.
In the public arena there has been much discussion on the benefits of for-profit private cord blood banking over public banking.Numerous for-profit companies offer new parents the option of collecting and storing cord blood for future use by the donor infant, siblings, or other family members.Parents may choose to bank cord blood if they have a family history of a particular disease or disorder, or as a means of biological insurance in case their child or family member develops a medical condition or becomes injured requiring a transplant.
While many diseases can be treated with a cord blood transplant, most require stem cells from another donor (allogeneic).Cord blood cells taken from the patient (autologous) typically contain the same defect or precancerous cells that caused the patient to need the transplant in the first place.Most medical professionals believe the chance that cord blood banking will be utilized by the patient or a close relative is relatively low.Estimates range from 1 out of 1,000 to 1 out of 200,000.From these estimates, privately stored cord blood is not likely to be utilized by the average family. The American Academy of Pediatrics has discouraged cord blood banking for self-use, since most diseases requiring stem cell transplants are already present in the cord blood stem cells. Additionally, a recent study published inPediatricsindicates that few transplants have been performed using privately stored cord blood.From the responses of 93 transplant physicians, in only 50 cases was privately banked blood used.In 9 of these cases the cord blood was transplanted back into the donor patient (autologous transplant).One of the main selling points of private cord blood banks is the possibility of a futureautologous transplant.
There is no significant opposition in the medical community to the public banking of cord blood.The donation of cord blood to public banks has generally been encouraged by the medical profession.The American Academy of Pediatrics encourages the public donation of cord blood with appropriate genetic and infectious disease testing, although they caution that parents should be notified that they will receive the results of this testing.They also recommend that parents be informed that publicly banked cord blood may not be available for future private use.
American Academy of Pediatrics Policy - Cord Blood Banking for Potential Future Transplantation
One oft cited argument against cord blood banking is that it is not known how long these cells can remain viable in storage.While it is not known if cells taken from an individual as an infant will be beneficial to them as an adult, units stored for up to 10 years have been transplanted successfully. This indicates that there is no reason to suggest serious deterioration in the quality of cord blood units stored for longer periods of time.
Public Cord Blood Banks:
Private Cord Blood Banks:
 During the processing stage excess red blood cells and plasma are removed reducing the volume to approximately 20 mL.
 F. Leonard Johnson, Placental blood transplantation and autologous banking: caveat emptor,Journal of Pediatric Hematology/Oncology19 (1997): 183 186.
 American Academy of Pediatrics Section on Hematology/Oncology, American Academy of Pediatrics Section on Allergy/Immunology, Bertram H. Lubin, and William T. Shearer,Cord Blood Banking for Potential Future Transplantation,Pediatrics119 (2007): 165-170.
 Ian Thornley, Mary Eapen, Lillian Sung, Stephanie J. Lee, Stella M. Davies and Steven Joffe, Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians,Pediatrics123 (2009): 1011-1017.
Cite as: Kirsten Riggan, "Cord Blood Stem Cells: An Overview, Dignitas 16, no. 1 (2009): 67.
- ThermoGenesis : The History of Cell and Gene Therapy - Marketscreener.com - April 14th, 2021
- Cord Blood Stem Cells Market 2021 Overview, Opportunities, In-Depth Analysis by 2027 : Becton, Dickinson and Company, DomaniCell, LLC, Future Health... - April 14th, 2021
- Umbilical Cord Blood (UCB) Stem Cell Market Booming CAGR +10% by 2028|| Osiris Therapeutics, Athersys, Opexa Therapeutics, NeoStem, Mesoblast Limited,... - April 14th, 2021
- Cord Blood Stem Cells Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Advanced Cell Technology, California Stem... - April 14th, 2021
- Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors - April 8th, 2021
- Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference - April 8th, 2021
- Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO - April 8th, 2021
- X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy - April 8th, 2021
- Cannalogue Expands Compassionate Care Program to Provide Lowest Medical Cannabis Price in Canada - April 8th, 2021
- Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors - April 8th, 2021
- Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases - April 8th, 2021
- Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- NKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer - April 8th, 2021
- CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting - April 8th, 2021
- AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a... - April 8th, 2021
- Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference - April 8th, 2021
- Cord Blood Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Advanced... - April 6th, 2021
- Cord Blood Stem Cells Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- Advanced Cell... - April 6th, 2021
- 25 Children with Autism Treated with Cord Blood: How Efficient is the Treatment? - Science Times - April 6th, 2021
- Latest Trending Report on Cord Blood Stem Cells Market by Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited,... - April 3rd, 2021
- The Governments Watchful Eye on Fraud Stemming from Stem Cell Therapy - JD Supra - April 3rd, 2021
- Hematopoietic Stem Cells Transplantation Market 2021 Analysis, Growth By Top Companies with Forecast 2025 : CBR Systems, ThermoGenesis, China Cord... - April 1st, 2021
- Why Hematopoietic Stem Cells Transplantation Market will be in Trend in Coming Period? Top Key Players- CBR Systems, China Cord Blood Corporation,... - April 1st, 2021
- Global Cell Isolation Market Sales Scenario of to Stay Positive Through 2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - April 1st, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top... - April 1st, 2021
- Global Autologous Stem Cell Based Therapies Market Industry Size, Future Trends, Development Strategy, Growth Factors, Top Players, Historical... - March 30th, 2021
- Hematopoietic Stem Cells HSCs Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- Kite Pharma... - March 30th, 2021
- Vita 34 continues to grow in 2020 in core markets after good year-end business - PharmiWeb.com - March 30th, 2021
- Biobanking Market | 2021 Global Industry Analysis by Covid-19 Impact On Healthcare Sector, Business with Forecast to 2027 The Bisouv Network - The... - March 30th, 2021
- Cord Blood Stem Cells Market to Witness Strong Growth Over 2021-2027 | Key Manufacturers Overview- Advanced Cell Technology, California Stem Cell,... - March 26th, 2021
- Stem Cell Assay Market Study Top Key Players, Application, Growth Analysis And Forecasts To 2016 2024 FLA News - FLA News - March 26th, 2021
- Inner Wheel Blayney held a cord blood fundraising event in the Community Centre - Blayney Chronicle - March 26th, 2021
- Research on Stem Cells Cryopreservation Equipments Market Key Data Points Necessary for Effective Strategies | Chart, Worthington Industries, Cesca... - March 26th, 2021
- Stem Cells Cryopreservation Equipments Market : Trends, Growth, Regions, Types and Key Developments, Applications By 2026 | Chart, Worthington... - March 26th, 2021
- Stem Cell Therapy Market- What Are The Main Factors That Contributing Towards Industry Growth? The Bisouv Network - The Bisouv Network - March 24th, 2021
- Stem cells from umbilical cords might be the answer for severely ill COVID patients: Canadian researchers - National Post - March 24th, 2021
- Global Stem Cell Banking Market Projected to Gain Significant Value by 2021-2025 The Bisouv Network - The Bisouv Network - March 24th, 2021
- Hematopoietic Stem Cell Transplantation Market to See Major Growth by 2026 | Gilead Sciences, Cesca Therapeutics, R&D Systems Investments Revolution... - March 22nd, 2021
- Umbilical Cord Blood Stem Cells - March 22nd, 2021
- Mouse embryos grow for days in culture, but the requirements are a bit nuts - Ars Technica - March 22nd, 2021
- Cell Transplant Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- Regen Biopharma, Global... - March 22nd, 2021
- [Full text] Early Detection of Negative Smoking Impacts: Vascular Adaptation Devia | VHRM - Dove Medical Press - March 22nd, 2021
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Top Key Players are including in this report: Regen Biopharma Inc, China Cord... - March 18th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% FLA News - FLA News - March 18th, 2021
- Research on Stem Cells Cryopreservation Equipments Market 2021 : By Growing Rate, Type, Applications, Geographical Regions, and Forecast to 2026 KSU... - March 18th, 2021
- Father, daughter honored for their work supporting nonprofit - dayton.com - March 18th, 2021
- Stem Cell Therapy Market Size | Growth, Opportunities, Trends And Forecast To 2027 Cabell Standard - Cabell Standard - March 18th, 2021
- Global Cell Transplant Market 2020 Overview of Vital Industry Drivers | Top Players Regen Biopharma , Global Cord Blood Corporation , Escape... - March 18th, 2021
- This is not science fiction. Israeli researchers have grown an embryo outside the womb - Haaretz - March 18th, 2021
- Global Stem Cells Cryopreservation Equipments Industry Market 2021 Overview, Opportunities, In-Depth Analysis by 2027:Sichuan mountain vertical, Cesca... - March 18th, 2021
- One step closer to treating spinal cord injury with our own stem cells - Speaking of Research - March 17th, 2021
- Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire - March 17th, 2021
- Global Cord Stem Cell Banking Market Is Expected To Bring In USD 13.8 Billion By 2026 - PharmiWeb.com - March 17th, 2021
- Global Stem Cells Banking Market 2026 : Analyse the Industry Developments and Investment Decisions of Esperite, Neostem, Smart Cells International ... - March 17th, 2021
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting... - March 17th, 2021
- Research Antibodies Market is Driven by Increasing Incidence of Chronic Diseases and Life-threatening Diseases KSU | The Sentinel Newspaper - KSU |... - March 17th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis, Growth, Emerging Trends, Opportunity and Forecast To 2027 FLA News - FLA News - March 17th, 2021
- Placental Stem Cell Therapy Market: Regenerative Ability to Develop into Other Types of Cells to Drive Global Market - BioSpace - March 13th, 2021
- Global Stem Cell Banking Market Comprehensive Study Explores Huge Growth Near in The Future||SMART CELLS PLUS, LifeCell International, Global Cord... - March 13th, 2021
- The Insight Partners's Detailed Report on Stem Cell Umbilical Cord Blood (UCB) Market Offers Projections of Potential Impact of Corona Virus Outbreak ... - March 11th, 2021
- Affimed Announces Presentations at the AACR Annual Meeting 2021 - GlobeNewswire - March 11th, 2021
- Cord Blood Stem Cells Market Trends 2021-2026 with Opportunities, Challenges and Companies' Profile Advanced Cell Technology, California Stem Cell,... - March 9th, 2021
- Stem Cell Therapy Useful In The Treatment Of A Range Of Diseases - Nerd's Magazine - March 9th, 2021
- Stem cells can give new life to ovaries and potentially restore fertility - Salon - March 7th, 2021
- Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells - DocWire News - March 7th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies... - March 5th, 2021
- Black people are three times less likely to find a bone marrow donor than white people - WLNS - March 5th, 2021
- Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide... - March 5th, 2021
- Global Hematopoietic Stem Cells Transplantation Market 2020 In-depth study, Size, Trends, Emerging Growth Factors and Regional Forecast to 2025 The... - March 5th, 2021
- Why Global Cord Blood Corporation Stock Is Jumping Today - Motley Fool - March 3rd, 2021
- NYCU shares lung therapy data with firms - - March 3rd, 2021
- Covid-19 Impact on Global Stem Cells Cryopreservation Equipments Market (2020-2025) | Potential growth, attractive valuation make it is a long-term... - March 3rd, 2021
- Autologous Stem Cell Based Therapies Market Analysis By Industry Value, Size, Top Companies And Growth Forecast To 2025 KSU | The Sentinel Newspaper... - March 3rd, 2021
- Global Cord Blood Corp.: Subscriber Growth Continues With 23% EPS CAGR And 25% FCF Yield - Seeking Alpha - March 3rd, 2021
- Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck - FierceBiotech - March 3rd, 2021
- Global Cord Blood Banking Services Market 2021 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by... - February 21st, 2021